STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency
STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency
This study will determine whether an experimental medicine, STA-5326 mesylate, is safe to use
 in patients with common variable immunodeficiency (CVID) who have inflammation of the gut. It
 will also determine if patients who take this drug show improvement in their symptoms,
 decrease in inflammatory chemicals in the gut, changes in their immune cells, and improvement
 in how their gut is functioning to absorb food.

 Patients between 18 and 75 years of age with CVID and chronic diarrhea or involuntary weight
 loss of more than 5 percent of their past body weight over the past 12 months may be eligible
 for this study. Candidates are screened with a review of their medical records, a medical
 history and physical examination, blood, urine and stool tests, chest x-rays and skin test
 for exposure to tuberculosis, and a hydrogen breath test. For the latter, breath samples are
 collected before and every 20 minutes (for 2 hours) after the subject drinks a sugar
 solution. This test determines the digestive effects of bacteria in the upper intestine.
 Samples are collected by having the subject blow into a balloon.

 Participants undergo the following tests and procedures:

 Immune System and Gastrointestinal Evaluation

 -  48-hour stool fat collection (measures the amount of undigested fat in the stool):
 Subjects keep a diary of what they eat for a 48-hour period. At the beginning of the 48
 hours they take two dye capsules and then take another two capsules 48 hours later. They
 collect a stool sample when they pass the second set of capsules in their bowel
 movement. An additional 24-hour stool collection is tested for loss of protein in the
 stool.

 -  D-xylose absorption test (measures the ability of the gut to absorb nutrients): Subjects
 drink a solution of d-xylose (a sugar substitute). Blood samples are collected before
 and 1 hour after drinking the solution.

 -  Upper endoscopy: A thin flexible lighted tube is advanced through the mouth to evaluate
 the esophagus, stomach and beginning of the small intestine.

 -  Lower endoscopy: A thin flexible lighted tube is advanced through the rectum to evaluate
 the colon.

 Treatment Period (Study days 1 to 57)

 -  Physical examination - study days 1, 8, 15, 29, 43 and 57

 -  Blood samples to test the levels of STA-5326 in the blood. On study days 1 and 57,
 samples are collected before the medication dose and 1, 2, 4, 6 and 8 hours after the
 dose; on day 29, one sample is collected before the medication dose.

 -  Blood samples for routine safety testing - study days 1, 8, 15, 29, 43 and 57

 -  Medication history - study days 1, 8, 15, 29, 43 and 57

 -  Interview about pain, discomfort, and well being - study days 1, 8, 15, 29, 43 and 57

 -  Pregnancy test for women who can become pregnant - study days 15, 43, and 57

 -  D-xylose absorption test - study days 29 and 57

 -  Electrocardiogram - study days 29 and 57

 -  Urine test - study days 29 and 57

 -  Blood test for research on immune cells - study day 57

 -  Repeat endoscopies and studies of gut function (24- and 48-hour stool collections)

 Follow-up period (Day 85 and day 113)

 -Physical examination, blood tests, medication history, questions about pain, discomfort and
 well being
The purpose of this study is to assess the toxicity of the oral IL-12/23 inhibitor STA-5326
 mesylate in subjects with common variable immunodeficiency (CVID) and associated symptomatic
 gastrointestinal inflammation. Common variable immunodeficiency is a clinically heterogeneous
 disorder characterized by decreased serum immunoglobulin IgG and IgA levels. In addition to
 chronic or recurrent pyogenic sino-pulmonary infections, many patients develop non-infectious
 gastrointestinal manifestations that can be disabling or fatal. Currently there is no
 standard therapy for the associated gastrointestinal disease outside of empiric nutritional
 intervention for weight loss and non-specific anti-diarrheal agents.

 Recently gut inflammation complicating CVID has been characterized as a Th1 inflammatory
 response, with excess cytokine production associated with diarrhea and weight loss as well as
 reduced D-xylose absorption and steatorrhea. This protocol represents the first attempt to
 test specific anti-IL-12 therapy in this patient group; it has been previously shown that
 therapy targeted to IL-12/23 successfully treated the Th1 gut inflammation of Crohn's
 disease. While this protocol is designed to measure the safety of STA-5326 mesylate in CVID
 patients, it will also measure effects on symptoms, gut function, expression of immune cell
 surface markers and production of cytokines from blood and gut mucosal mononuclear cells.

 CVID patients with gastrointestinal symptoms of malabsorption, maldigestion, and chronic
 diarrhea will be enrolled into this study. Subjects (up to a total of 10 individuals) will
 receive STA-5326 mesylate 100 mg per os (PO) once daily (QD) (equivalent to 70 mg STA-5326
 free base) for 8 weeks. Subjects will have pretreatment and end-of-study procedures,
 including upper and lower endoscopies, to measure changes in immune responses and physiologic
 measures of gut function, as well as routine safety monitoring throughout the treatment
 period. Variables will include safety (adverse event rate), clinical (weight, stool
 frequency, results of gut absorption tests), and laboratory (lymphocyte and cytokine assays)
 parameters for descriptive summary statistical analysis (n, mean, median, standard deviation,
 minimum and maximum range).
-  INCLUSION CRITERIA:

 A subject is eligible for the study if all of the following criteria are met:

 Has given written informed consent prior to screening.

 Is male or female aged 18 through 75 years.

 Has CVID diagnosed definitively prior to screening (based on the IUIS criteria).

 Has a documented, unintended loss of greater than 5% of their body weight over the last
 year or requires nutritional supplements to maintain his/her body weight OR has chronic
 diarrhea defined as a complaint of liquid stools for at least 4 consecutive weeks (and an
 output of greater than 200 g stool/24hr on a diet of at least 1600 calories with 60 g fat.)

 If taking oral antibiotics chronically, must have used a stable dose of the antibiotic
 continuously for at least 2 weeks prior to start of screening period.

 Not taking any potential CYP3A4 inhibitors/inducers (e.g., macrolide antibiotics, HIV
 protease inhibitors, antifungals, grapefruit juice, St. John's Wort).

 EXCLUSION CRITERIA:

 A subject is excluded from the study if any of the following criteria are met:

 General Criteria:

 Has any clinically significant disease (e.g., renal, hepatic, neurological, cardiovascular,
 pulmonary, endocrinologic, psychiatric, hematologic, urologic, or other acute or chronic
 illness) that in the opinion of the investigator would make the subject an unsuitable
 candidate for this trial.

 Is a woman who has a positive serum pregnancy test or who is breast-feeding.

 Is a woman of childbearing potential or a man who does not agree to use two forms of
 contraception during the course of the study and follow-up period.

 Has hypersensitivity to any of the components of STA 5326 mesylate drug product.

 Has any of the following clinical chemistry values:

 AST greater than 2.5 x upper limit of normal (ULN).

 ALT greater than 2.5 x ULN.

 Serum bilirubin greater than 1.5 x ULN.

 Serum creatinine greater than 1.5 x ULN.

 Alkaline phosphatase greater than 2.5 x ULN.

 Has a hemoglobin level less than 9 g/dL or hematocrit less than 30%.

 Has a Prothromin Time INR greater than 1.3 or a Partial Thromboplastin Time greater than 3
 sec compared to control value.

 Has the following cell counts (cells/microliter):

 Platelet count less than 90,000 or greater than 800,000.

 White blood cell count less than 1,500.

 Neutrophil count less than 900.

 Has a current infection requiring intravenous antibiotics, a serious local infection (e.g.,
 cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia).

 Has a history of cancer within the past 5 years, with the exception of excised basal cell
 carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ.

 Had a dependency for any illicit drug, chemical, or alcohol within the past 5 years.

 Has a history of active tuberculosis (or a CXR with findings suggestive of old TB infection
 including calcified nodular lesions, apical fibrosis, or pleural scarring), acute or
 chronic hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

 Gastrointestinal Criteria:

 Has a stool sample positive for gastrointestinal infection during screening.

 Has a positive hydrogen breath test

 Prior Medication Criteria:

 Received parenteral corticosteroids within 1 month prior to receiving study drug. The use
 of short-term or single-dose corticosteroids as a pretreatment regimen for IVIG is
 acceptable.

 Received any investigational drug within 3 months prior to receiving study drug.

 Received cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 2 months
 prior to receiving study drug.

 Received any biological product (e.g., infliximab, adalimumab, natalizumab, etc.) within 3
 months prior to receiving study drug.

 Ever received treatment with STA-5326 mesylate, anti-IL 12 antibodies, or other specific IL
 12 inhibitors.